FDA has expanded the approved uses of ribociclib (Kisqali) for women with advanced breast cancer, including new uses in pre- and postmenopausal women. It’s the first approval under a new FDA program to speed the review of cancer drugs.
from Cancer Currents: An NCI Cancer Research Blog https://ift.tt/2LbnBJy